{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:03:54Z","timestamp":1794891834261,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Skeletal muscle disease severity can often progress asymmetrically across muscle groups and heterogeneously within tissues. An example is Duchenne Muscular Dystrophy (DMD) in which lack of dystrophin results in devastating skeletal muscle wasting in some muscles whereas others are spared or undergo hypertrophy. An efficient, non-invasive approach to identify sites of asymmetry and degenerative lesions could enable better patient monitoring and therapeutic targeting of disease. In this study, we utilized a versatile intravenously injectable mesoporous silica nanoparticle (MSNP) based nanocarrier system to explore mechanisms of biodistribution in skeletal muscle of <jats:italic>mdx<\/jats:italic> mouse models of DMD including wildtype, dystrophic, and severely dystrophic mice. Moreover, MSNPs could be imaged in live mice and whole muscle tissues enabling investigation of how biodistribution is altered by different types of muscle pathology such as inflammation or fibrosis. We found MSNPs were tenfold more likely to aggregate within select <jats:italic>mdx<\/jats:italic> muscles relative to wild type, such as gastrocnemius and quadriceps. This was accompanied by decreased biodistribution in off-target organs. We found the greatest factor affecting preferential delivery was the regenerative state of the dystrophic skeletal muscle with the highest MSNP abundance coinciding with the regions showing the highest level of embryonic myosin staining and intramuscular macrophage uptake. To demonstrate, muscle regeneration regulated MSNP distribution, we experimentally induced regeneration using barium chloride which resulted in a threefold increase of intravenously injected MSNPs to sites of regeneration 7\u00a0days after injury. These discoveries provide the first evidence that nanoparticles have selective biodistribution to skeletal muscle in DMD to areas of active regeneration and that nanoparticles could enable diagnostic and selective drug delivery in DMD skeletal muscle.<\/jats:p>","DOI":"10.1186\/s12951-023-01994-0","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T02:01:44Z","timestamp":1693274504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Nanoparticles systemically biodistribute to regenerating skeletal muscle in DMD"],"prefix":"10.1186","volume":"21","author":[{"given":"Michael R.","family":"Hicks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kholoud","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Mokhonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Pyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"key":"1994_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052502","author":"C Sanchez Riera","year":"2021","unstructured":"Sanchez Riera C, et al. Muscle diversity, heterogeneity, and gradients: learning from sarcoglycanopathies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052502.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1994_CR2","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1172\/JCI133303","volume":"130","author":"D Bosnakovski","year":"2020","unstructured":"Bosnakovski D, et al. Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice. J Clin Invest. 2020;130(5):2465\u201377.","journal-title":"J Clin Invest"},{"issue":"5","key":"1994_CR3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd TE, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83(5):426\u201333.","journal-title":"Neurology"},{"issue":"1","key":"1994_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/jnnp-2017-316736","volume":"89","author":"G Tasca","year":"2018","unstructured":"Tasca G, et al. MRI in sarcoglycanopathies: a large international cohort study. J Neurol Neurosurg Psychiatry. 2018;89(1):72\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1994_CR5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","volume":"52","author":"C Webster","year":"1988","unstructured":"Webster C, et al. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 1988;52(4):503\u201313.","journal-title":"Cell"},{"issue":"1","key":"1994_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pmr.2011.11.014","volume":"23","author":"JN Kornegay","year":"2012","unstructured":"Kornegay JN, et al. The paradox of muscle hypertrophy in muscular dystrophy. Phys Med Rehabil Clin N Am. 2012;23(1):149\u201372.","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"3","key":"1994_CR7","first-page":"151","volume":"36","author":"SM Chrzanowski","year":"2017","unstructured":"Chrzanowski SM, et al. Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy. Acta Myol. 2017;36(3):151\u201362.","journal-title":"Acta Myol"},{"issue":"3","key":"1994_CR8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1039\/C8NR07769J","volume":"11","author":"X Han","year":"2019","unstructured":"Han X, et al. Applications of nanoparticles in biomedical imaging. Nanoscale. 2019;11(3):799\u2013819.","journal-title":"Nanoscale"},{"key":"1994_CR9","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.6b06040","author":"B Pelaz","year":"2017","unstructured":"Pelaz B, et al. Diverse applications of nanomedicine. ACS Nano. 2017. https:\/\/doi.org\/10.1021\/acsnano.6b06040.","journal-title":"ACS Nano"},{"issue":"12","key":"1994_CR10","first-page":"742","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. Pharmacy Therap. 2017;42(12):742.","journal-title":"Pharmacy Therap"},{"issue":"19","key":"1994_CR11","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.7150\/thno.27847","volume":"8","author":"C Schumann","year":"2018","unstructured":"Schumann C, et al. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. Theranostics. 2018;8(19):5276\u201388.","journal-title":"Theranostics"},{"key":"1994_CR12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, et al. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Rel. 2016;240:332\u201348.","journal-title":"J Control Rel"},{"issue":"1","key":"1994_CR13","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1038\/s41467-018-06730-z","volume":"9","author":"P Dogra","year":"2018","unstructured":"Dogra P, et al. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. Nat Commun. 2018;9(1):4551.","journal-title":"Nat Commun"},{"issue":"2","key":"1994_CR14","first-page":"313","volume":"77","author":"R Vracko","year":"1974","unstructured":"Vracko R. Basal lamina scaffold-anatomy and significance for maintenance of orderly tissue structure: a review. Am J Pathol. 1974;77(2):313.","journal-title":"Am J Pathol"},{"issue":"3","key":"1994_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0026-2862(79)90041-4","volume":"18","author":"RG Tilton","year":"1979","unstructured":"Tilton RG, Kilo C, Williamson JR. Pericyte-endothelial relationships in cardiac and skeletal muscle capillaries. Microvasc Res. 1979;18(3):325\u201335.","journal-title":"Microvasc Res"},{"issue":"1","key":"1994_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0040-8166(80)90061-0","volume":"12","author":"TK Borg","year":"1980","unstructured":"Borg TK, Caulfield JB. Morphology of connective tissue in skeletal muscle. Tissue Cell. 1980;12(1):197\u2013207.","journal-title":"Tissue Cell"},{"issue":"9","key":"1994_CR17","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ajpath.2015.05.009","volume":"185","author":"C Latroche","year":"2015","unstructured":"Latroche C, et al. Structural and functional alterations of skeletal muscle microvasculature in dystrophin-deficient mdx mice. Am J Pathol. 2015;185(9):2482\u201394.","journal-title":"Am J Pathol"},{"issue":"21","key":"1994_CR18","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1161\/01.CIR.0000147776.50787.74","volume":"110","author":"S Straino","year":"2004","unstructured":"Straino S, et al. Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation. 2004;110(21):3341\u20138.","journal-title":"Circulation"},{"issue":"11","key":"1994_CR19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","volume":"60","author":"II Slowing","year":"2008","unstructured":"Slowing II, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278\u201388.","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"1994_CR20","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1039\/c0jm03851b","volume":"21","author":"Q He","year":"2011","unstructured":"He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011;21(16):5845\u201355.","journal-title":"J Mater Chem"},{"issue":"12","key":"1994_CR21","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/adma.201104763","volume":"24","author":"F Tang","year":"2012","unstructured":"Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504\u201334.","journal-title":"Adv Mater"},{"issue":"1","key":"1994_CR22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cm402592t","volume":"26","author":"C Argyo","year":"2013","unstructured":"Argyo C, et al. Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem Mater. 2013;26(1):435\u201351.","journal-title":"Chem Mater"},{"issue":"17","key":"1994_CR23","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/adfm.201302988","volume":"24","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, et al. Biocompatible, uniform, and redispersible mesoporous silica nanoparticles for cancer-targeted drug delivery in vivo. Adv Func Mater. 2014;24(17):2450\u201361.","journal-title":"Adv Func Mater"},{"issue":"10","key":"1994_CR24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/ar2000259","volume":"44","author":"JE Lee","year":"2011","unstructured":"Lee JE, et al. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res. 2011;44(10):893\u2013902.","journal-title":"Acc Chem Res"},{"issue":"4","key":"1994_CR25","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acsnano.5b00510","volume":"9","author":"H Meng","year":"2015","unstructured":"Meng H, et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9(4):3540\u201357.","journal-title":"ACS Nano"},{"issue":"2","key":"1994_CR26","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acsnano.5b07781","volume":"10","author":"X Liu","year":"2016","unstructured":"Liu X, et al. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer. ACS Nano. 2016;10(2):2702\u201315.","journal-title":"ACS Nano"},{"issue":"5","key":"1994_CR27","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1172\/JCI92284","volume":"127","author":"X Liu","year":"2017","unstructured":"Liu X, et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Investig. 2017;127(5):2007\u201318.","journal-title":"J Clin Investig"},{"issue":"2","key":"1994_CR28","volume":"10","author":"ME Nance","year":"2018","unstructured":"Nance ME, et al. Nanotherapy for Duchenne muscular dystrophy. Wiley Interdisci Rev Nanomed Nanobiotechnol. 2018;10(2): e1472.","journal-title":"Wiley Interdisci Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"1994_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/nat.2013.0450","volume":"24","author":"MS Falzarano","year":"2014","unstructured":"Falzarano MS, Passarelli C, Ferlini A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther. 2014;24(1):87\u2013100.","journal-title":"Nucleic Acid Ther"},{"key":"1994_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.201900061","author":"MR Emami","year":"2019","unstructured":"Emami MR, Young CS, Ji Y, Liu X, Mokhonova E, Pyle AD, Meng H, Spencer MJ. Polyrotaxane nanocarriers can deliver CRISPR\/Cas9 plasmid to dystrophic muscle cells to successfully edit the DMD gene. Adv Therap. 2019. https:\/\/doi.org\/10.1002\/adtp.201900061.","journal-title":"Adv Therap"},{"issue":"7","key":"1994_CR31","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/nl100991w","volume":"10","author":"V Cauda","year":"2010","unstructured":"Cauda V, et al. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett. 2010;10(7):2484\u201392.","journal-title":"Nano Lett"},{"issue":"5","key":"1994_CR32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nmat2992","volume":"10","author":"CE Ashley","year":"2011","unstructured":"Ashley CE, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389.","journal-title":"Nat Mater"},{"issue":"1","key":"1994_CR33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/acsnano.8b06164","volume":"13","author":"X Liu","year":"2019","unstructured":"Liu X, et al. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer. ACS Nano. 2019;13(1):38\u201353.","journal-title":"ACS Nano"},{"issue":"4","key":"1994_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/adfm.200600578","volume":"17","author":"K Moeller","year":"2007","unstructured":"Moeller K, Kobler J, Bein T. Colloidal suspensions of nanometer-sized mesoporous silica. Adv Func Mater. 2007;17(4):605\u201312.","journal-title":"Adv Func Mater"},{"issue":"5","key":"1994_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006019","volume":"12","author":"KM Lamar","year":"2016","unstructured":"Lamar KM, et al. Overexpression of latent TGFbeta binding protein 4 in muscle ameliorates muscular dystrophy through myostatin and TGFbeta. PLoS Genet. 2016;12(5): e1006019.","journal-title":"PLoS Genet"},{"issue":"12","key":"1994_CR36","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1172\/JCI39845","volume":"119","author":"A Heydemann","year":"2009","unstructured":"Heydemann A, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest. 2009;119(12):3703\u201312.","journal-title":"J Clin Invest"},{"issue":"1","key":"1994_CR37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41556-017-0010-2","volume":"20","author":"MR Hicks","year":"2018","unstructured":"Hicks MR, et al. ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol. 2018;20(1):46\u201357.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1994_CR38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2012.05.046","volume":"163","author":"T Yu","year":"2012","unstructured":"Yu T, et al. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release. 2012;163(1):46\u201354.","journal-title":"J Control Release"},{"issue":"10","key":"1994_CR39","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.biomaterials.2012.12.043","volume":"34","author":"C Fu","year":"2013","unstructured":"Fu C, et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013;34(10):2565\u201375.","journal-title":"Biomaterials"},{"issue":"4","key":"1994_CR40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/wnan.143","volume":"3","author":"A Chrastina","year":"2011","unstructured":"Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdisci Rev Nanomed Nanobiotechnol. 2011;3(4):421\u201337.","journal-title":"Wiley Interdisci Rev Nanomed Nanobiotechnol"},{"issue":"4","key":"1994_CR41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cm.10022","volume":"51","author":"ML Springer","year":"2002","unstructured":"Springer ML, Ozawa CR, Blau HM. Transient production of alpha-smooth muscle actin by skeletal myoblasts during differentiation in culture and following intramuscular implantation. Cell Motil Cytoskeleton. 2002;51(4):177\u201386.","journal-title":"Cell Motil Cytoskeleton"},{"key":"1994_CR42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-3810-0_5","volume":"1460","author":"MT Tierney","year":"2016","unstructured":"Tierney MT, Sacco A. Inducing and evaluating skeletal muscle injury by notexin and barium chloride. Methods Mol Biol. 2016;1460:53\u201360.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1994_CR43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13395-019-0213-2","volume":"9","author":"AB Morton","year":"2019","unstructured":"Morton AB, et al. Barium chloride injures myofibers through calcium-induced proteolysis with fragmentation of motor nerves and microvessels. Skelet Muscle. 2019;9(1):27.","journal-title":"Skelet Muscle"},{"issue":"6","key":"1994_CR44","doi-asserted-by":"crossref","first-page":"104444","DOI":"10.1016\/j.isci.2022.104444","volume":"25","author":"AA Cutler","year":"2022","unstructured":"Cutler AA, et al. The regenerating skeletal muscle niche drives satellite cell return to quiescence. iScience. 2022;25(6):104444.","journal-title":"iScience"},{"key":"1994_CR45","doi-asserted-by":"publisher","DOI":"10.3791\/57524","author":"JT Brash","year":"2018","unstructured":"Brash JT, Ruhrberg C, Fantin A. Evaluating vascular hyperpermeability-inducing agents in the skin with the miles assay. J Vis Exp. 2018. https:\/\/doi.org\/10.3791\/57524.","journal-title":"J Vis Exp"},{"issue":"299","key":"1994_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1126\/scitranslmed.aaa7322","volume":"7","author":"AS Rosenberg","year":"2015","unstructured":"Rosenberg AS, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7(299):299.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1994_CR47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41565-018-0356-z","volume":"14","author":"F Peng","year":"2019","unstructured":"Peng F, et al. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotechnol. 2019;14(3):279\u201386.","journal-title":"Nat Nanotechnol"},{"issue":"314","key":"1994_CR48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1126\/scitranslmed.aac6522","volume":"7","author":"MA Miller","year":"2015","unstructured":"Miller MA, et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med. 2015;7(314):314.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1994_CR49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0960-8966(97)00115-6","volume":"7","author":"V Brussee","year":"1997","unstructured":"Brussee V, Tardif F, Tremblay JP. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromuscul Disord. 1997;7(8):487\u201392.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1994_CR50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/JP282292","volume":"600","author":"NL Jacobsen","year":"2022","unstructured":"Jacobsen NL, et al. Myofibre injury induces capillary disruption and regeneration of disorganized microvascular networks. J Physiol. 2022;600(1):41\u201360.","journal-title":"J Physiol"},{"key":"1994_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal0225","author":"MA Miller","year":"2017","unstructured":"Miller MA, et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aal0225.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1994_CR52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/hmg\/ddn376","volume":"18","author":"SA Villalta","year":"2009","unstructured":"Villalta SA, et al. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009;18(3):482\u201396.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1994_CR53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ntno.30052","volume":"3","author":"D Reichel","year":"2019","unstructured":"Reichel D, Tripathi M, Perez JM. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment. Nanotheranostics. 2019;3(1):66\u201388.","journal-title":"Nanotheranostics"},{"key":"1994_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh3693","author":"TM Raimondo","year":"2021","unstructured":"Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abh3693.","journal-title":"Sci Adv"},{"issue":"6335","key":"1994_CR55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/352536a0","volume":"352","author":"HH Stedman","year":"1991","unstructured":"Stedman HH, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991;352(6335):536\u20139.","journal-title":"Nature"},{"key":"1994_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050969","author":"WM MacCuaig","year":"2022","unstructured":"MacCuaig WM, et al. Toxicity assessment of mesoporous silica nanoparticles upon intravenous injection in mice: implications for drug delivery. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14050969.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1994_CR57","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1021\/acsnano.8b04910","volume":"12","author":"D Breznan","year":"2018","unstructured":"Breznan D, et al. Physicochemical properties can be key determinants of mesoporous silica nanoparticle potency in vitro. ACS Nano. 2018;12(12):12062\u201379.","journal-title":"ACS Nano"},{"issue":"7","key":"1994_CR58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IE Verhaart","year":"2019","unstructured":"Verhaart IE, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373\u201386.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1994_CR59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell. 2016;18(4):533\u201340.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"1994_CR60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, et al. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech. 2015;8(3):195\u2013213.","journal-title":"Dis Model Mech"},{"issue":"3","key":"1994_CR61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12031-007-9023-9","volume":"34","author":"M Vainzof","year":"2008","unstructured":"Vainzof M, et al. Animal models for genetic neuromuscular diseases. J Mol Neurosci. 2008;34(3):241\u20138.","journal-title":"J Mol Neurosci"},{"key":"1994_CR62","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.omtn.2019.09.020","volume":"18","author":"F Barthelemy","year":"2019","unstructured":"Barthelemy F, et al. Targeting RyR activity boosts antisense exon 44 and 45 skipping in human DMD skeletal or cardiac muscle culture models. Mol Ther Nucleic Acids. 2019;18:580\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1994_CR63","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo E, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12(1):7101.","journal-title":"Nat Commun"},{"key":"1994_CR64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.actbio.2020.10.009","volume":"118","author":"D Huang","year":"2020","unstructured":"Huang D, et al. Polymeric nanoparticles functionalized with muscle-homing peptides for targeted delivery of phosphatase and tensin homolog inhibitor to skeletal muscle. Acta Biomater. 2020;118:196\u2013206.","journal-title":"Acta Biomater"},{"issue":"10","key":"1994_CR65","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.ymthe.2020.08.020","volume":"28","author":"X Gao","year":"2020","unstructured":"Gao X, et al. Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol Ther. 2020;28(10):2299\u2013301.","journal-title":"Mol Ther"},{"issue":"2","key":"1994_CR66","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/nl404316v","volume":"14","author":"D Shen","year":"2014","unstructured":"Shen D, et al. Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres. Nano Lett. 2014;14(2):923\u201332.","journal-title":"Nano Lett"},{"issue":"9","key":"1994_CR67","doi-asserted-by":"crossref","first-page":"8325","DOI":"10.1021\/acsnano.6b02819","volume":"10","author":"PN Durfee","year":"2016","unstructured":"Durfee PN, et al. Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells. ACS Nano. 2016;10(9):8325\u201345.","journal-title":"ACS Nano"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T06:23:44Z","timestamp":1700288624000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01994-0","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"29 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal and biosafety studies were approved by the UCLA ARC and IRB. There is no human subjects research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Pyle and Dr. Spencer are co-founders and scientific advisory board members to MyoGene Bio. Drs. Pyle and Spencer have a financial interest in MyoGene Bio and the UC Regents has licensed IP that we invented to MyoGene Bio.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"303"}}